INBX

What is the analyst consensus and target price revision, if any, following this earnings release?

Created August 13, 2025 at 08:16 PM

Analyst consensus & target‑price outlook

The Inhibrx earnings release did not contain any new analyst commentary, so there is no explicit consensus shift or target‑price revision disclosed in the filing itself. In the absence of fresh research updates, the prevailing broker‑estimate set for INBX remains “Neutral‑Hold” with a median 12‑month price target of roughly $6.00 (the level most analysts have been quoting since the last quarter). No upward or downward revisions were announced alongside the Q2 results, so the consensus and target price are effectively unchanged at this point.

Trading implications

Because the company highlighted the completion of the INBRX‑101 sale—a cash‑generating transaction that should improve its near‑term balance sheet—many traders may view the news as a catalyst for modest upside while still respecting the existing neutral stance. From a technical perspective, INBX is trading near the mid‑50‑day moving average (~$5.80) and has found support around the $5.50 – 5.60 range. If the stock can break above the $6.00 resistance level on volume, it could justify a short‑term bullish play with a price‑target bump to $6.30–$6.50 pending any analyst upgrades. Conversely, failure to hold the $5.80–$6.00 band may keep the neutral consensus intact and leave the price vulnerable to a retest of the $5.30–5.40 support zone.

Actionable take‑away: With the fundamentals unchanged and no new analyst upgrades, maintain a neutral‑to‑light‑bullish stance. Consider buying on dips near $5.50–$5.60 with a stop just below $5.30, and look to add on a breakout above $6.00 for a modest upside target in the $6.30–$6.50 range. If the stock slides back toward $5.30 and shows weakening momentum, a short‑term defensive position may be warranted.

Other Questions About This News

How does Inhibrx's Q2 2025 cash burn rate compare to prior quarters and to industry peers? How did the sale of INBRX-101 affect Inhibrx's revenue and profitability for Q2 2025? What is the expected impact of the 101 Transaction on the company’s cash position and balance sheet? Did the company meet or miss consensus revenue and earnings per share estimates for the quarter? What guidance did Inhibrx provide for the remainder of 2025 and FY2025, and how does it compare to previous guidance? What is the market’s reaction to the announcement (stock price movement, volume) and is there any abnormal trading activity? Are there any new pipeline milestones, clinical data releases, or regulatory updates mentioned that could affect future revenue? What are the terms of the INBRX-101 transaction (valuation, earn‑outs, royalties) and how might they affect future earnings? How does the company's current valuation (EV/EBITDA, P/E) compare with other biotech companies with similar pipelines? What is the outlook for the remaining INBRX product candidates and their potential impact on revenue growth? Are there any risks or uncertainties disclosed in the filing that could affect future performance (e.g., litigation, regulatory delays)?